Nonalcoholic fatty liver disease is associated with significant coronary artery disease in type 2 diabetic patients: A computed tomography angiography study

Journal of Diabetes

Volumn 7, Issue 2, 2015, Pages 279-286

  Idilman, Ilkay S ^a   Akata, Deniz ^a   Hazirolan, Tuncay ^a   Doganay Erdogan, Beyza ^b   Aytemir, Kudret ^a   Karcaaltincaba, Musturay ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Coronary artery disease; Coronary computed tomography angiography; Nonalcoholic fatty liver disease; Type 2 diabetes mellitus

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETIC PATIENT; DISEASE ASSOCIATION; FEMALE; HUMAN; IMAGE PROCESSING; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RISK ASSESSMENT; THORAX PAIN; ANALYSIS; ANGIOCARDIOGRAPHY; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; CROSS-SECTIONAL STUDY; FOLLOW UP; GLUCOSE BLOOD LEVEL; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

GLUCOSE BLOOD LEVEL;

ADULT; AGED; BLOOD GLUCOSE; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84924099832     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12172     Document Type: Article

References (36)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346: 1221-1231.
2. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology. 2003; 37: 1202-1219.
3. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology. 2009; 49: 306-317.
4. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: A review and update. Dig Dis Sci. 2010; 55: 560-578.
5. Creutzfeldt W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. Prog Liver Dis. 1970; 3: 371-407.
6. Marchesini G, Bugianesi E, Forlani G etal. Nonalcoholic fatty liver, steatohepatitis, and metabolic syndrome. Hepatology. 2003; 37: 917-923.
7. Pagano G, Pacini G, Musso G etal. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence of an etiologic association. Hepatology. 2002; 35: 367-372.
8. Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: A case control study. Arterioscler Thromb Vasc Biol. 2005; 16: 421-427.
9. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010; 363: 1341-1350.
10. Treeprasertsuk S, Lopez-Jimenez F, Lindor KD. Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci. 2011; 56: 35-45.
11. Terry JG, Carr JJ, Tang R etal. Coronary artery calcium outperforms carotid artery intima-media thickness as a noninvasive index of prevalent coronary artery stenosis. Arterioscler Thromb Vasc Biol. 2005; 25: 1723-1728.
12. Detrano R, Guerci AD, Carr JJ etal. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008; 358: 1336-1345.
13. Bravo A, Sheth S, Chopra S. Liver biopsy. N Engl J Med. 2001; 344: 495-500.
14. Ratziu V, Charlotte F, Heurtier A etal. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005; 128: 1898-1906.
15. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009; 51: 433-445.
16. Kodama Y, Nq CS, Wu TT etal. Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol. 2007; 188: 1307-1312.
17. Schlett CL, Banerji D, Siegel E etal. Prognostic value of CT angiography for major adverse cardiac events in patients with acute chest pain from the emergency department: 2-year outcomes of the ROMICAT trial. JACC Cardiovasc Imaging. 2011; 4: 481-491.
18. Villines TC, Hulten EA, Shaw LJ etal. Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography: Results from the CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter) registry. J Am Coll Cardiol. 2011; 58: 2533-2540.
19. World Health Organization. Report of A WHO Consultation: Definition of Metabolic Syndrome in Definition, Diagnosis and Classification of Diabetes Mellitus. World Health organization, Department of Noncommunicable Disease Surveillance, Geneva, 1999.
20. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of A WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. World Health Organization, Geneva, 1999.
21. Park SH, Kim PN, Kim KW etal. Macrovesicular hepatic steatosis in living liver donors: Use of CT for quantitative and qualitative assessment. Radiology. 2006; 239: 105-112.
22. Targher G, Bertoluni L, Padovani R etal. Prevalance of non-alcoholic fatty liver disease and its association with cardiovascular disease among type two diabetic patients. Diabetes Care. 2007; 30: 1212-1218.
23. Boyce CJ, Pickhardt PJ, Kim DH, Hinshaw LJ, Taylor AJ, Winter TC. Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low dose CT. AJR Am J Roentgenol. 2010; 194: 623-628.
24. Hamaguchi M, Kojima T, Takeda N etal. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007; 13: 1579-1584.
25. Targher G, Bertolini L, Rodella S etal. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007; 30: 2119-2121.
26. Wong VW, Wong GL, Yip GW etal. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut. 2011; 12: 1721-1727.
27. Kim D, Choi SY, Park EH etal. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology. 2012; 56: 605-613.
28. McKimmie RL, Daniel KR, Carr JJ etal. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: The Diabetes Heart Study. Am J Gastroenterol. 2008; 103: 3029-3035.
29. Petit JM, Guiu B, Terriat B etal. Non-alcoholic fatty liver is not associated with carotid intima-media thickness in type 2 diabetic patients. J Clin Endocrinol Metab. 2009; 94: 4103-4106.
30. Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology. 2010; 254: 393-400.
31. Lim S, Shin H, Lee Y etal. Effect of metabolic syndrome on coronary artery stenosis and plaque characteristics as assessed with 64-detector row cardiac CT. Radiology. 2011; 261: 437-445.
32. Strasak AM, Kelleher CC, Klenk J etal. Longitudinal change in serum gammaglutamyl transferase and cardiovascular disease mortality: A prospective population-based study in 76, 113 Austrian adults. Arterioscler Thromb Vasc Biol. 2008; 28: 1857-1865.
33. Schindhelm RK, Dekker JM, Nijpels G etal. Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn study. Atherosclerosis. 2007; 191: 391-396.
34. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Le SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology. 2006; 43: 1145-1151.
35. Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD. Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: Pooling of three British Health Surveys. J Hepatol. 2012; 57: 1083-1089.
36. Ekstedt M, Franzén LE, Mathiesen UL etal. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006; 44: 865-873.